In addition, significant associations between circulating SDC1 and the outcome of patients with other tumor entities including lung cancer (33, 34), prostate cancer (35), bladder cancer (36), and multiple myeloma (37) have been reported in the literature. This evidence concerns the gene SDC1 and AL amyloidosis.